Top

Published in:

Open Access 01-02-2008 | Epidemiology

Estrogen receptor α polymorphisms and postmenopausal breast cancer risk

Authors: A. M. González-Zuloeta Ladd, A. Arias Vásquez, F. Rivadeneira, C. Siemes, A. Hofman, B. H. Ch. Stricker, H. A. P. Pols, A. G. Uitterlinden, C. M. van Duijn

Published in: Breast Cancer Research and Treatment | Issue 3/2008

Abstract

Background

The estrogen receptor alpha (ESR1) is a mediator of estrogen response in the breast. The most studied variants in this gene are the PvuII and XbaI polymorphisms, which have been associated to lower sensitivity to estrogen. We evaluated whether these polymorphisms were associated with breast cancer risk by means of an association study in a population of Caucasian postmenopausal women from the Rotterdam study and a meta-analysis of published data.

Methods

The PvuII and XbaI polymorphisms were genotyped in 3,893 women participants of the Rotterdam Study. Baseline information was obtained through a questionnaire. We conducted logistic regression analyses to assess the risk of breast cancer by each of the ESR1 genotypes. Meta-analyses of all publications on these relations were done by retrieving literature from Pubmed and by further checking the reference lists of the articles obtained.

Results

There were 38 women with previously diagnosed breast cancer. During follow-up, 152 were additionally diagnosed. The logistic regression analyses showed no difference in risk for postmenopausal breast cancer in carriers of the PvuII or XbaI genotypes neither in overall, incident or prevalent cases. No further evidence of a role of these variants was found in the meta-analysis.

Conclusions

Our results suggest that the ESR1 polymorphisms do not play a role in breast cancer risk in Caucasian postmenopausal women.

Hulka BS, Moorman PG (2001) Breast cancer: hormones and other risk factors. Maturitas 38(1):103–13; discussion 113–116

Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M et al (2000) Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343(2):78–85PubMedCrossRef

Feigelson HS, Henderson BE (2000) Future possibilities in the prevention of breast cancer: role of genetic variation in breast cancer prevention. Breast Cancer Res 2(4):277–282PubMedCrossRef

Shin A, Kang D, Nishio H, Lee MJ, Park SK, Kim SU et al (2003) Estrogen receptor alpha gene polymorphisms and breast cancer risk. Breast Cancer Res Treat 80(1):127–131PubMedCrossRef

Han W, Kang D, Lee KM, Kim HJ, Ahn SJ, Kim SW et al (2003) Full sequencing analysis of estrogen receptor-alpha gene polymorphism and its association with breast cancer risk. Anticancer Res 23(6C):4703–4707PubMed

Gosden JR, Middleton PG, Rout D (1986) Localization of the human oestrogen receptor gene to chromosome 6q24—q27 by in situ hybridization. Cytogenet Cell Genet 43(3–4):218–220PubMed

Ponglikitmongkol M, Green S, Chambon P (1988) Genomic organization of the human oestrogen receptor gene. Embo J 7(11):3385–3388PubMed

Castagnoli A, Maestri I, Bernardi F, Del Senno L (1987) PvuII RFLP inside the human estrogen receptor gene. Nucleic Acids Res 15(2):866PubMedCrossRef

Andersen TI, Heimdal KR, Skrede M, Tveit K, Berg K, Borresen AL (1994) Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility. Hum Genet 94(6):665–670PubMed

10.

Cai Q, Shu XO, Jin F, Dai Q, Wen W, Cheng JR et al (2003) Genetic polymorphisms in the estrogen receptor alpha gene and risk of breast cancer: results from the Shanghai breast cancer study. Cancer Epidemiol Biomarkers Prev 12(9):853–859PubMed

11.

Kang HJ, Kim SW, Kim HJ, Ahn SJ, Bae JY, Park SK et al (2002) Polymorphisms in the estrogen receptor-alpha gene and breast cancer risk. Cancer Lett 178(2):175–180PubMedCrossRef

12.

Modugno F, Zmuda JM, Potter D, Cai C, Ziv E, Cummings SR et al(2005) Association of estrogen receptor alpha polymorphisms with breast cancer risk in older Caucasian women. Int J Cancer 116(6):984–991PubMedCrossRef

13.

Yaich L, Dupont WD, Cavener DR, Parl FF (1992) Analysis of the PvuII restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood. Cancer Res 52(1):77–83PubMed

14.

van Meurs JB, Schuit SC, Weel AE, van der Klift M, Bergink AP, Arp PP et al (2003) Association of 5′ estrogen receptor alpha gene polymorphisms with bone mineral density, vertebral bone area and fracture risk. Hum Mol Genet 12(14):1745–1754PubMedCrossRef

15.

Schuit SC, van Meurs JB, Bergink AP, van der Klift M, Fang Y, Leusink G et al (2004) Height in pre- and postmenopausal women is influenced by estrogen receptor alpha gene polymorphisms. J Clin Endocrinol Metab 89(1):303–309PubMedCrossRef

16.

Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA (1991) Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 7(4):403–422PubMedCrossRef

17.

Garrow J (1986) Quetelet index as indicator of obesity. Lancet 1(8491):1219PubMedCrossRef

18.

Raymond MRF (1986) Genepop (version 1.2): population genetics software for exact tests and ecumenism. J Heredity 86:248–249

19.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188PubMedCrossRef

20.

Macaskill P, Walter SD, Irwig L (2001) A comparison of methods to detect publication bias in meta-analysis. Stat Med 20(4):641–654PubMedCrossRef

21.

Shen Y, Li DK, Wu J, Zhang Z, Gao E (2006) Joint effects of the CYP1A1 MspI, ERalpha PvuII, and ERalpha XbaI polymorphisms on the risk of breast cancer: results from a population-based case-control study in Shanghai, China. Cancer Epidemiol Biomarkers Prev 15(2):342–347PubMedCrossRef

22.

Wedren S, Lovmar L, Humphreys K, Magnusson C, Melhus H, Syvanen AC, et al (2004) Oestrogen receptor alpha gene haplotype and postmenopausal breast cancer risk: a case control study. Breast Cancer Res 6(4):R437–R449PubMedCrossRef

23.

Comings DE, Gade-Andavolu R, Cone LA, Muhleman D, MacMurray JP (2003) A multigene test for the risk of sporadic breast carcinoma. Cancer 97(9):2160–2170PubMedCrossRef

24.

Onland-Moret NC, van Gils CH, Roest M, Grobbee DE, Peeters PH (2005) The estrogen receptor alpha gene and breast cancer risk (The Netherlands). Cancer Causes Control 16(10):1195–1202PubMedCrossRef

Title: Estrogen receptor α polymorphisms and postmenopausal breast cancer risk
Authors: A. M. González-Zuloeta Ladd
A. Arias Vásquez
F. Rivadeneira
C. Siemes
A. Hofman
B. H. Ch. Stricker
H. A. P. Pols
A. G. Uitterlinden
C. M. van Duijn
Publication date: 01-02-2008
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9562-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2008

Role of Fra-2 in breast cancer: influence on tumor cell invasion and motility

Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk

Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network

Advanced stages and poorly differentiated grade are associated with an increased risk of HER2/neu positive breast carcinoma only in White women: findings from a prospective cohort study of African-American and White-American women

Unique resistance of breast carcinoma cell line T47D to TRAIL but not anti-Fas is linked to p43cFLIPL

Detection of the CHEK2 1100delC mutation by MLPA BRCA1/2 analysis: a worthwhile strategy for its clinical applicability in 1100delC low-frequency populations?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer